IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
Open accessThe DOI matches its Crossref record; 30 of the 31 references it cites were found in a registry or an index.
Abstract
Programmed death-1-directed (PD-1-directed) immune checkpoint blockade results in durable antitumor activity in many advanced malignancies. Recent studies suggest that IFN-γ is a critical driver of programmed death ligand-1 (PD-L1) expression in cancer and host cells, and baseline intratumoral T cell infiltration may improve response likelihood to anti-PD-1 therapies, including pembrolizumab. However, whether quantifying T cell-inflamed microenvironment is a useful pan-tumor determinant of PD-1-directed therapy response has not been rigorously evaluated. Here, we analyzed gene expression profiles (GEPs) using RNA from baseline tumor samples of pembrolizumab-treated patients. We identified immune-related signatures correlating with clinical benefit using a learn-and-confirm paradigm based on data from different clinical studies of pembrolizumab, starting with a small pilot of 19 melanoma patients and eventually defining a pan-tumor T cell-inflamed GEP in 220 patients with 9 cancers. Predictive value was independently confirmed and compared with that of PD-L1 immunohistochemistry in 96 patients with head and neck squamous cell carcinoma. The T cell-inflamed GEP contained IFN-γ-responsive genes related to antigen presentation, chemokine expression, cytotoxic activity, and adaptive immune resistance, and these features were necessary, but not always sufficient, for clinical benefit. The T cell-inflamed GEP has been developed into a clinical-grade assay that is currently being evaluated in ongoing pembrolizumab trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The degree of tumor inflammation, as assessed by the presence of type I/II IFN signaling and infiltrating effector T cells, is associated with an improved response to checkpoint immunotherapy (8–11,13).”
From Reimagining IDO Pathway Inhibition in Cancer Immunotherapy via Downstream Focus on the Tryptophan–Kynurenine–Aryl Hydrocarbon Axis (2019) · cites this paper as [8]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Defects associated with this pathway and its downstream effectors have shown both negative and positive correlations with response to ICB, suggesting a dual role for this pathway in tumor immunity (Ayers et al., 2017; Gao et al., 2016).”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Ayers et al., 2017
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Several gene signatures capturing the inflamed components of the TME have been associated with a favourable response to ICIs69,72,78–81, but none has been clinically validated thus far.”
From Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024) · cites this paper as [81]
The cited source says what the claim attributes to it.
In the citing paper
“Interferon (IFN) signaling through the Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway plays a prominent role in tumor immunity.”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Ayers et al., 2017
The cited source says what the claim attributes to it.
In the citing paper
“In the clinic, a strong IFN-γ signature has been identified as a useful predictor and indicator of response in anti-PD-1-treated patients across various cancer indications (75,92,93).”
From Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance (2021) · cites this paper as [93]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Regularization and Variable Selection Via the Elastic Net
Zou, H., & Hastie, T. (2005) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.1467-9868.2005.00503.x · Cited by 20,957
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838 · cited 1×
“org Volume 127 Number 8 August 2017 Introduction Cancer cells have the ability to adapt to and avoid host immune checkpoints and surveillance as a means to promote their continued survival (1, 2).”
BackgroundMutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Oncology meets immunology: the cancer-immunity cycle.
Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609 · cited 1×
“These data extend the observations of previous reports showing that CD8+ T lymphocytes and T cell active chemokines and T cell counterinhibitory molecules such as PD-1/PD-L1 and IDO1 are coregulated within tumors (4, 15, 21, 22) and confirm that response to anti–PD-1 blockade occurs primarily in patients with such a p…”
ResultSelf-citationPembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198 · cited 1×
“Newer genomic technologies can be used to evaluate complexities of tumor and Recently, increased PD-L1 expression on the surface of tumor cells has been identified as an important determinant of response to immune therapies targeting the PD-1 axis (16).”
BackgroundSelf-citationPD-1 and Its Ligands in Tolerance and Immunity
Keir, M. E., Butte, M. J., Freeman, G. J., & Sharpe, A. H. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090331 · Cited by 5,378
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231 · cited 2×
“Likewise, these data provide a much higher level of statistical validation across multiple tumor types than has previously been reported for single genes associated with the IFN-γ signaling pathway and response to PD-1 blockade (17), indicating that integrated multigene signatures might represent more robust predictiv…”
Background
Cited by
Items 601–700 of 1,011
Yang, F., Wang, J., Wang, Y., Liu, B., & Molina, J. R. (2021) · Cancers · doi:10.3390/cancers14010109 · Cited by 83
Zhao, T., Zeng, J., Xu, Y., Su, Z., Chong, Y., Ling, T., Xu, H., Shi, H. R., Zhu, M., Mo, Q., et al. (2022) · Theranostics · doi:10.7150/thno.75069 · Cited by 79
Cai, Z., Chen, J., Yu, Z.-Z., Li, H., Liu, Z., Deng, D., Liu, J., Chen, C., Zhang, C., Ou, Z., et al. (2023) · Advanced Science · doi:10.1002/advs.202207155 · Cited by 86
Outh-Gauer, S., Alt, M., Tourneau, C. L., Augustin, J., Broudin, C., Gasne, C., Denize, T., Mirghani, H., Fabre, E., Ménard, M., et al. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.02.008 · Cited by 78
The Tumor Microenvironment in Colorectal Cancer Therapy
Pedrosa, L., Esposito, F., Thomson, T. M., & Maurel, J. (2019) · Cancers · doi:10.3390/cancers11081172 · Cited by 69
The “ART” of Epigenetics in Melanoma: From histone “Alterations, to Resistance and Therapies”
Strub, T., Ballotti, R., & Bertolotto, C. (2020) · Theranostics · doi:10.7150/thno.36218 · Cited by 77
Habtetsion, T. G., Ding, Z., Pi, W., Li, T., Lu, C., Chen, T., Xi, C., Spartz, H., Liu, K., Hao, Z., et al. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.05.012 · Cited by 82
“Moreover, some recent studies have revealed novel mechanisms by which T cell-derived IFNγ remodels the TME to promote antitumor immunity (Ayers et al., 2017; Sharma et al., 2018; Wang et al., 2016).”
BackgroundTelli, M. L., Nagata, H., Wapnir, I., Acharya, C. R., Zablotsky, K., Fox, B. A., Bifulco, C. B., Jensen, S. M., Ballesteros‐Merino, C., Le, M. H., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3944 · Cited by 77
Roussel, M., Le, K.-S., Granier, C., Llamas‐Gutierrez, F., Foucher, E. D., Gallou, S. L., Pangault, C., Xerri, L., Launay, V., Lamy, T., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020003080 · Cited by 78
Role of CXCR3 signaling in response to anti-PD-1 therapy
Han, X., Wang, Y., Sun, J., Tan, T., Cai, X., Lin, P., Tan, Y., Zheng, B., Wang, B., Wang, J., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.08.067 · Cited by 75
Park, C., Na, K. J., Choi, H., Ock, C.-Y., Ha, S., Kim, M., Park, S., Keam, B., Kim, T. M., Paeng, J. C., et al. (2020) · Theranostics · doi:10.7150/thno.50283 · Cited by 71
Szabó, P. M., Vajdi, A., Kumar, N., Tolstorukov, M. Y., Chen, B. J., Edwards, R. H., Ligon, K. L., Chasalow, S. D., Chow, K.-H., Shetty, A., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-28480-9 · Cited by 79
Zhang, N., Zhang, H., Liu, Z., Dai, Z., Wu, W., Zhou, R., Li, S., Wang, Z., Liang, X., Wen, J., et al. (2023) · Cell Proliferation · doi:10.1111/cpr.13409 · Cited by 81
Dong, Y., Gao, Q., Chen, Y., Zhang, Z., Du, Y., Liu, Y., Zhang, G., Li, S., Wang, G., Chen, X., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-38232-y · Cited by 79
Rini, B. I., Plimack, E. R., Stus, V. P., Gafanov, R. A., Waddell, T., Nosov, D., Pouliot, F., Alekseev, B. Y., Soulières, D., Melichar, B., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03867-5 · Cited by 96
Self-citationBatf3+ DCs and type I IFN are critical for the efficacy of neoadjuvant cancer immunotherapy
Liu, J., Rozeman, E. A., O’Donnell, J. S., Allen, S., Fanchi, L., Smyth, M. J., Blank, C. U., & Teng, M. W. L. (2019) · OncoImmunology · doi:10.1080/2162402x.2018.1546068 · Cited by 70
IL-27 confers a protumorigenic activity of regulatory T cells via CD39
Park, Y.-J., Ryu, H., Choi, G., Kim, B. S., Hwang, E. S., Kim, H. S., & Chung, Y. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1810254116 · Cited by 74
“This cytokine also induces suppressive molecules such as PD-L1, CTLA-4, and IDO (28, 29).”
BackgroundPD ‐ L1 and PD ‐ L2 expression correlated genes in non‐small‐cell lung cancer
Vilsbøll, T., Hussmann, D., & Nielsen, A. L. (2019) · 癌症:英文版 · doi:10.1186/s40880-019-0376-6 · Cited by 82
“With previous studies showing that both PD-L1 and PD-L2 genes are regulated by IFN signaling, we focused on IFN signaling as an important driving mechanism for the expression of PD-L1 and PD-L2 [21, 40].”
BackgroundResultYu, S., Sha, H., Qin, X., Chen, Y., Li, X., Shi, M., & Feng, J. (2020) · Oncogene · doi:10.1038/s41388-020-1182-y · Cited by 71
Clinical and genomic characterisation of mismatch repair deficient pancreatic adenocarcinoma
Grant, R. C., Denroche, R. E., Jang, G. H., Nowak, K. M., Zhang, A. X. W., Borgida, A., Holter, S., Topham, J. T., Wilson, J. M., Dodd, A., et al. (2020) · Gut · doi:10.1136/gutjnl-2020-320730 · Cited by 79
Potential Role of CXCL13/CXCR5 Signaling in Immune Checkpoint Inhibitor Treatment in Cancer
Hsieh, C.-H., Jian, C.-Z., Lin, L., Low, G.-S., Ou, P.-Y., Hsu, C., & Ou, D. (2022) · Cancers · doi:10.3390/cancers14020294 · Cited by 73
Casarrubios, M., Provencio, M., Nadal, E., Insa, A., García-Campelo, R., Lázaro-Quintela, M., Dómine, M., Majem, M., Rodríguez‐Abreu, D., Martínez‐Martí, A., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005320 · Cited by 79
Immunotherapy for hepatocellular carcinoma: Recent advances and future targets
Yu, S. J. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108387 · Cited by 73
Cancer immune exclusion: breaking the barricade for a successful immunotherapy
Bruni, S., Mercogliano, M. F., Mauro, F. L., Russo, R. I. C., & Schillaci, R. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1135456 · Cited by 79
Nadal, E., Saleh, M. N., Ponce-Aix, S., Ochoa-de-Olza, M., Patel, S. P., Antonia, S. J., Zhao, Y., Gueorguieva, I., Man, M. Z., Estrem, S. T., et al. (2023) · BMC Cancer · doi:10.1186/s12885-023-11153-1 · Cited by 78
Huang, M., Chen, Y., Lyu, W.-Y., He, X., Ye, Z.-H., Huang, C.-Y., He, X., Chen, X., Chen, X., Zhang, B., et al. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106988 · Cited by 73
Falk, A. T., Yazbeck, N., Guibert, N. M., Chamorey, E., Paquet, A. C., Ribeyre, L., Bence, C., Zahaf, K., Leroy, S., Marquette, C., et al. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.05.009 · Cited by 71
Nitric Oxide-Mediated Enhancement and Reversal of Resistance of Anticancer Therapies
Hays, E., & Bonavida, B. (2019) · Antioxidants · doi:10.3390/antiox8090407 · Cited by 74
“(A) YY1 mediates the expression of PD-L1 in tumor cells, leading to CTL-mediated immune resistance.”
InfluentialLuke, J. J., Onderdonk, B. E., Bhave, S. R., Karrison, T., Lemons, J. M., Chang, P. J., Zha, Y., Carll, T., Krausz, T. N., Huang, L., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1790 · Cited by 73
Lin, H., Scull, B., Goldberg, B. R., Abhyankar, H. A., Eckstein, O. S., Zinn, D. J., Lubega, J., Agrusa, J. E., Mallawaney, N. E., Gulati, N., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021004287 · Cited by 70
Wang, H., Zhou, Y., Zhang, Y., Fang, S., Zhang, M., Li, H., Xu, F., Liu, L., Liu, J., Zhao, Q., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004302 · Cited by 73
Evolutionary route of nasopharyngeal carcinoma metastasis and its clinical significance
Mei, L., Zhang, X.-L., You, R., Liu, Y., Cai, H., Liu, L., Liu, X., Zou, X., Xie, Y., Zou, R., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-35995-2 · Cited by 79
Pulanco, M. C., Madsen, A. T., Tanwar, A., Corrigan, D. T., & Zang, X. (2023) · Cellular and Molecular Immunology · doi:10.1038/s41423-023-01019-8 · Cited by 74
Response to Anti–PD-1 in Uveal Melanoma Without High-Volume Liver Metastasis
Johnson, D. B., Bao, R., Ancell, K. K., Daniels, A. B., Wallace, D. E., Sosman, J. A., & Luke, J. J. (2019) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.7070 · Cited by 69
Comprehensive analysis of cutaneous and uveal melanoma liver metastases
Hoefsmit, E. P., Rozeman, E. A., Van, T. M., Dimitriadis, P., Krijgsman, O., Conway, J. W., da Silva, I. P., van der Wal, J. E., Ketelaars, S. L. C., Bresser, K., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001501 · Cited by 73
Friedrich, M., Jasinski‐Bergner, S., Lazaridou, M., Subbarayan, K., Massa, C., Tretbar, S., Mueller, A., Handke, D., Biehl, K., Bukur, J., et al. (2019) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-019-02373-1 · Cited by 72
Pearson, A. D. J., Rössig, C., Lesa, G. M., Diede, S. J., Weiner, S. L., Anderson, J., Gray, J. C., Geoerger, B., Minard‐Colin, V., Marshall, L. V., et al. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2019.12.029 · Cited by 73
Immunotherapy for sarcomas: new frontiers and unveiled opportunities
Birdi, H. K., Jirovec, A., Cortés-Kaplan, S., Werier, J. A., Nessim, C., Diallo, J., & Ardolino, M. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001580 · Cited by 78
MHC Class I Deficiency in Solid Tumors and Therapeutic Strategies to Overcome It
Shklovskaya, E., & Rizos, H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22136741 · Cited by 78
Park, J., Kwon, M., Kim, K. H., Kim, T.-S., Hong, S.-H., Kim, C. G., Kang, S., Moon, J. H., Kim, E. H., Park, S., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2564 · Cited by 71
Self-citationZhang, J., Caruso, F. P., Sa, J. K., Justesen, S. F. L., Nam, D., Sims, P. A., Ceccarelli, M., Lasorella, A., & Iavarone, A. (2019) · Communications Biology · doi:10.1038/s42003-019-0369-7 · Cited by 72
Jordan, K. R., Sikora, M. J., Slansky, J. E., Minic, A. D., Richer, J. K., Moroney, M. R., Hu, J., Wolsky, R. J., Watson, Z. L., Yamamoto, T. M., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1762 · Cited by 79
Gajewski, T. F., & Higgs, E. F. (2020) · Science · doi:10.1126/science.abc6622 · Cited by 69
Borràs, D. M., Verbandt, S., Ausserhofer, M., Sturm, G., Lim, J., Verge, G. A., Vanmeerbeek, I., Laureano, R. S., Govaerts, J., Sprooten, J., et al. (2023) · Cell Discovery · doi:10.1038/s41421-023-00605-4 · Cited by 67
Noblejas‐López, M. D. M., Nieto‐Jiménez, C., Morcillo-García, S., Pérez‐Peña, J., Nuncia‐Cantarero, M., Pretel, F. A., Galán‐Moya, E. M., Amir, E., Pandiella, A., Győrffy, B., et al. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1629780 · Cited by 87
Yao, Y., Yan, Z., Lian, S., Wei, L., Chao Hui, Z. H. O. U., Feng, D., Zhang, Y., Yang, J., Li, M., & Chen, Y. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000444 · Cited by 67
“Thus, our novel predictive biomarkers, which include genetic characteristics, may not only provide novel insights into the underlying mechanisms and biological behaviors associated with HNSCC but may also benefit clinical decision-making for patients in the future.”
Xiong, H., Ma, X., Wang, X., Su, W., Wu, L., Zhang, T., Xu, Z., & Sun, Z. (2021) · Advanced Functional Materials · doi:10.1002/adfm.202100007 · Cited by 68
The Tumor Microenvironment of Bladder Cancer
Hatogai, K., & Sweis, R. F. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-59038-3_17 · Cited by 81
Holzgruber, J., Martins, C. P., Kulcsár, Z., Duplaine, A., Rasbach, E., Migayron, L., Singh, P. K., Statham, E., Landsberg, J., Boniface, K., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-51496-2 · Cited by 78
Geva, R., Voskoboynik, M., Dobrenkov, K., Mayawala, K., Gwo, J., Wnek, R., Chartash, E., & Long, G. V. (2020) · Cancer · doi:10.1002/cncr.33133 · Cited by 66
Distinct tumor microenvironments of lytic and blastic bone metastases in prostate cancer patients
Ihle, C. L., Provera, M. D., Straign, D. M., Smith, E. E., Edgerton, S. M., van Bokhoven, A., Lucia, M. S., & Owens, P. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0753-3 · Cited by 86
Liu, D., Yang, X., & Wu, X.-Z. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.663495 · Cited by 80
Prakadan, S. M., Alvarez-Breckenridge, C. A., Markson, S. C., Kim, A. E., Klein, R. H., Nayyar, N., Navia, A. W., Kuter, B. M., Kolb, K. E., Bihun, I. V., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25860-5 · Cited by 73
Chida, K., Kawazoe, A., Suzuki, T., Kawazu, M., Ueno, T., Takenouchi, K., Nakamura, Y., Kuboki, Y., Kotani, D., Kojima, T., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-0041 · Cited by 69
Annexin A2/TLR2/MYD88 pathway induces arginase 1 expression in tumor-associated neutrophils
Zhang, H., Zhu, X., Friesen, T. J., Kwak, J., Pisarenko, T., Mekvanich, S., Velasco, M. A., Randolph, T. W., Kargl, J., & Houghton, A. M. (2022) · Journal of Clinical Investigation · doi:10.1172/jci153643 · Cited by 72
Wang, Q., Li, G., Ma, X., Liu, L., Liu, J., Yin, Y., Li, H., Chen, Y., Zhang, X., Zhang, L., et al. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-05609-2 · Cited by 66
Bringing the Next Generation of Immuno-Oncology Biomarkers to the Clinic
Cesano, A., & Warren, S. E. (2018) · Biomedicines · doi:10.3390/biomedicines6010014 · Cited by 73
Cancer Vaccines: Steering T Cells Down the Right Path to Eradicate Tumors
Ott, P. A., & Wu, C. J. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1357 · Cited by 72
Kazmierski, W. M., Xia, B., Miller, J. F., la Rosa, M. D., Favre, D., Dunham, R. M., Washio, Y., Zhu, Z., Wang, F., Mebrahtu, M., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01799 · Cited by 65
Lü, Z., Chen, H., Li, S., Gong, J., Li, J., Zou, J., Wu, L., Yu, J., Han, W., Sun, H., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000374 · Cited by 71
Xia, L., Zheng, Z., Liu, J., Chen, Y.-J., Ding, J., Hu, G.-S., Hu, Y.-H., Liu, S., Luo, W., Xia, N., et al. (2021) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-20-0405 · Cited by 83
Chen, S., Xie, Y., Cai, Y., Hu, H., He, M., Liu, L., Liao, C., Wang, Y., Wang, J., Ren, X., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1157 · Cited by 66
PD-L1 expression in medulloblastoma: an evaluation by subgroup
Martin, A. M., Nirschl, C. J., Polanczyk, M. J., Bell, W. R., Nirschl, T. R., Harris‐Bookman, S., Phallen, J. A., Hicks, J. L., Martínez, D., Ogurtsova, A., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.24951 · Cited by 67
Immunotherapy for Urothelial Carcinoma: Current Evidence and Future Directions
Tripathi, A., & Plimack, E. R. (2018) · Current Urology Reports · doi:10.1007/s11934-018-0851-7 · Cited by 70
Strategies for developing and optimizing cancer vaccines
Maeng, H. M., & Berzofsky, J. A. (2019) · F1000Research · doi:10.12688/f1000research.18693.1 · Cited by 68
Ascierto, P. A., Bifulco, C. B., Palmieri, G., Peters, S., & Sidiropoulos, N. (2019) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2019.05.004 · Cited by 66
SLAMF6 as a Regulator of Exhausted CD8+ T Cells in Cancer
Yigit, B., Wang, N., ten Hacken, E., Chen, S., Bhan, A. K., Suárez‐Fueyo, A., Katsuyama, E., Tsokos, G. C., Chiorazzi, N., Wu, C. J., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0664 · Cited by 69
Bomane, A., Gonçalvès, A., & Ballester, P. J. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.01041 · Cited by 66
“For instance, gene expression signatures were identified and evaluated using 81 melanoma patients to predict their response to PD-1 checkpoint inhibitors (Ayers et al., 2017).”
Clinical and immune profiling for cancer of unknown primary site
Haratani, K., Hayashi, H., Takahama, T., Nakamura, Y., Tomida, S., Yoshida, T., Chiba, Y., Sawada, T., Sakai, K., Fujita, Y., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0720-z · Cited by 68
Targeting STAT3 and STAT5 in Tumor-Associated Immune Cells to Improve Immunotherapy
Verdeil, G., Lawrence, T., Schmitt‐Verhulst, A., & Auphan‐Anezin, N. (2019) · Cancers · doi:10.3390/cancers11121832 · Cited by 70
Identification of gastric cancer subtypes based on pathway clustering
Li, L., & Wang, X. (2021) · npj Precision Oncology · doi:10.1038/s41698-021-00186-z · Cited by 72
Cai, Y., Ji, W., Sun, C., Xu, R., Chen, X., Deng, Y., Pan, J., Yang, J., Zhu, H., & Mei, J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.704965 · Cited by 69
“Information on 122 immunomodulators, well-known effector genes of tumor-infiltrating immune cells (TIICs), and 18 specific genes associated with T-cell inflammation and their weighting coefficients was collected from previous studies (16, 17).”
BackgroundMethodCampbell, M. T., Matin, S. F., Tam, A. L., Sheth, R. A., Ahrar, K., Tidwell, R. S. S., Rao, P., Karam, J. A., Wood, C. G., Tannir, N. M., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26415-4 · Cited by 65
Nakayama, Y., Mimura, K., Tamaki, T., Shiraishi, K., Kua, L., Koh, V., Ohmori, M., Kimura, A., Inoue, S., Okayama, H., et al. (2019) · International Journal of Oncology · doi:10.3892/ijo.2019.4779 · Cited by 70
MAPK pathway mutations in head and neck cancer affect immune microenvironments and ErbB3 signaling
Ngan, H.-L., Liu, Y., Fong, A., Poon, P. H. Y., Yeung, C. K., Chan, S. S. M., Lau, A., Piao, W., Li, H., Tse, J. S. W., et al. (2020) · Life Science Alliance · doi:10.26508/lsa.201900545 · Cited by 70
“Antitumor IFN-γ score was the weighted arithmetic mean of the TPM of 18 IFN-γ expanded immune gene signatures as previously described by (Ayers et al, 2017).”
Mitchell, K. G., Diao, L., Karpinets, T. V., Negrao, M. V., Tran, H. T., Parra, E. R., Corsini, E. M., Reuben, A., Federico, L., Bernatchez, C., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000405 · Cited by 71
“In this study, we identified associations between circulating neutrophil expansion with disease burden and protumorigenic systemic signaling in a prospectively enrolled cohort of patients who underwent primary NSCLC resection.”
Shklovskaya, E., & Rizos, H. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21197139 · Cited by 73
Bossi, P., Alfieri, S., Strojan, P., Takes, R. P., López, F., Mäkitie, A. A., Saba, N. F., Rodrigo, J. P., Bradford, C. R., Suarez, C. M., et al. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2019.01.018 · Cited by 64
Amato, C. M., Hintzsche, J. D., Wells, K. R., Applegate, A. J., Gorden, N. T., Vorwald, V. M., Tobin, R. P., Nassar, K. W., Shellman, Y. G., Kim, J., et al. (2020) · Cancers · doi:10.3390/cancers12071943 · Cited by 66
Wang, H. Q., Mulford, I. J., Sharp, F., Liang, J., Kurtulus, S., Trabucco, G., Quinn, D. S., Longmire, T. A., Patel, N., Patil, R., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-0189 · Cited by 60
Cancer neoantigens as potential targets for immunotherapy
Ma, W., Pham, B., & Li, T. (2021) · Clinical & Experimental Metastasis · doi:10.1007/s10585-021-10091-1 · Cited by 68
Even, C., Wang, H., Li, S.-H., Ngan, R. K. C., Dechaphunkul, A., Zhang, L., Yen, C., Chan, P. C., Chakrabandhu, S., Ma, B. B. Y., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0822 · Cited by 63
Horr, C., & Buechler, S. A. (2021) · npj Breast Cancer · doi:10.1038/s41523-021-00345-2 · Cited by 69
Hurst, C. D., Cheng, G., Platt, F. M., Castro, M. A. A., Marzouka, N., Eriksson, P., Black, E. V. I., Alder, O., Lawson, A. R. J., Lindskrog, S. V., et al. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100472 · Cited by 69
Targeting Cancer Cell Ferroptosis to Reverse Immune Checkpoint Inhibitor Therapy Resistance
Deng, J., Zhou, M. L., Liao, T., Kuang, W., Xia, H., Yin, Z., Tan, Q., Li, Y., Song, S., Zhou, E., et al. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.818453 · Cited by 68
Akbar, S., Raza, A., Mohsin, R., Kanbour, A., Qadri, S. M., Parray, A., Gul, A. R. Z., Philip, A., Vijayakumar, S., Merhi, M., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1097117 · Cited by 70
Cottrell, T. R., Lotze, M. T., Ali, A., Bifulco, C. B., Capitini, C. M., Chow, L. Q. M., Cillo, A. R., Collyar, D. E., Cope, L., Deutsch, J. S., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-010928 · Cited by 69
Immune microenvironment of triple-negative breast cancer in African-American and Caucasian women
O’Meara, T. A., Safonov, A. M., Casadevall, D., Qing, T., Silber, A. L. M., Killelea, B. K., Hatzis, C., & Pusztai, L. (2019) · Breast Cancer Research and Treatment · doi:10.1007/s10549-019-05156-5 · Cited by 63
Kaderbhaï, C., Tharin, Z., & Ghiringhelli, F. (2019) · Cancers · doi:10.3390/cancers11020201 · Cited by 69
“Transcriptomic IFN signature High expression is associated with better efficacy of anti PD-1 [14]”
BackgroundMethodResultLiu, R., Yang, F., Yin, J., Liu, Y., Zhang, W., & Zhou, H. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.685370 · Cited by 77
Immune checkpoint inhibitors in urothelial cancer: recent updates and future outlook
Gopalakrishnan, D., Koshkin, V. S., Ornstein, M. C., Papatsoris, A., & Grivas, P. D. (2018) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s158753 · Cited by 65
A Dual Role of Type I Interferons in Antitumor Immunity
Zhou, L., Zhang, Y., Wang, Y., Zhang, M., Sun, W., Dai, T., Wang, A., Wu, X., Zhang, S., Wang, S., et al. (2020) · Advanced Biosystems · doi:10.1002/adbi.201900237 · Cited by 64
Proia, T. A., Singh, M., Woessner, R. D., Carnevalli, L. S., Bommakanti, G., Magiera, Ł., Srinivasan, S. S., Grosskurth, S. E., Collins, M. P., Womack, C., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1066 · Cited by 65
NOTCH3 is a Prognostic Factor and Is Correlated With Immune Tolerance in Gastric Cancer
Cui, Y., Li, Q., Li, W., Wang, Y., Lv, F., Shi, X., Tang, Z., Shen, Z., Hou, Y., Zhang, H., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.574937 · Cited by 62
“Regarding the IFN-g signature (35), there was no significant difference between the two groups (Figure 5E).”
BackgroundMultiancestry genomic and transcriptomic analysis of gastric cancer
Totoki, Y., Saito-Adachi, M., Shiraishi, Y., Komura, D., Nakamura, H. K., Suzuki, A., Tatsuno, K., Rokutan, H., Hama, N., Yamamoto, S., et al. (2023) · Nature Genetics · doi:10.1038/s41588-023-01333-x · Cited by 71
Fraterman, I., Reijers, I. L. M., Dimitriadis, P., Broeks, A., Gonzalez, M., Menzies, A. M., López‐Yurda, M., Kapiteijn, E., van der Veldt, A. A. M., Suijkerbuijk, K. P. M., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02631-x · Cited by 74
Wawrzyniak, P., & Hartman, M. L. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02294-x · Cited by 72
Pantaleo, M. A., Tarantino, G., Agostinelli, C., Urbini, M., Nannini, M., Saponara, M., Castelli, C., Stacchiotti, S., Fumagalli, E. R., Gatto, L., et al. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1617588 · Cited by 62
Unique T-Cell Populations Define Immune-Inflamed Hepatocellular Carcinoma
Blasi, D. D., Boldanova, T., Mori, L., Terracciano, L., Heim, M. H., & Libero, G. D. (2019) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2019.08.004 · Cited by 64
Schett, A., Rothschild, S. I., Fontecedro, A. C., Krähenbühl, S., Früh, M., Schmid, S., Driessen, C., & Joerger, M. (2019) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-019-03993-1 · Cited by 67
Metadata
- Authors
- Ayers, M., Lunceford, J., Nebozhyn, M., Murphy, E., Loboda, A., Kaufman, D. R., Albright, A., Cheng, J. D., Kang, S. P., Shankaran, V., Piha-Paul, S. A., Yearley, J., Seiwert, T. Y., Ribas, A., & McClanahan, T. K.
- Affiliations
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- University of Washington (US)
- The University of Texas MD Anderson Cancer Center (US)
- University of Chicago (US)
- University of California, Los Angeles (US)
- Corresponding author
- McClanahan, Terrill K.
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2017-06-26
- Volume
- 127
- Issue
- 8
- Pages
- 2930-2940
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- PMC
- PMC5531419
- OpenAlex
- W2655262992
- Cited by
- 3,788
- References
- 31
- Citations by year
- 2026: 358 · 2025: 391 · 2024: 518 · 2023: 551 · 2022: 608 · 2021: 512 · 2020: 400 · 2019: 263 · 2018: 159 · 2017: 24
- FWCI
- 101.33
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- interferon-gamma, anti-PD-1 therapy, pembrolizumab, predictive biomarkers, gene expression profiles, PD-L1 expression, immune checkpoint inhibitors, melanoma, head and neck squamous cell carcinoma, adaptive immune resistance, antigen presentation, chemokine expression
- MeSH terms
- Antineoplastic Agents, Biopsy, Carcinoma, Carcinoma, Non-Small-Cell Lung, Humans, Immune System, Immunohistochemistry, Interferon-gamma, Lung Neoplasms, Melanoma, Pilot Projects, ROC Curve, Skin Neoplasms, Stomach Neoplasms, Signal Transduction, Gene Expression Regulation, Neoplastic, Treatment Outcome, Sequence Analysis, RNA, Gene Expression Profiling, Tumor Microenvironment, B7-H1 Antigen, Programmed Cell Death 1 Receptor, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.